Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

Core Insights - Erasca, Inc. has reported significant clinical progress for its RAS-targeting franchise, with early clinical activity observed for ERAS-0015 and ERAS-4001, including confirmed partial responses in multiple tumor types with different RAS mutations [1][2] Pipeline Progress and Milestones - ERAS-0015 is positioned as a potential best-in-class RAS-targeting molecule, with initial Phase 1 monotherapy data expected in the first half of 2026 and further expansion cohorts planned for the second half of 2026 [3][5] - ERAS-4001 is a potential first-in-class pan-KRAS inhibitor, with initial Phase 1 monotherapy data anticipated in the second half of 2026 and expansion cohorts planned for 2027 [4][7] Clinical Data and Efficacy - During the ongoing AURORAS-1 Phase 1 trial, ERAS-0015 has shown promising early clinical activity, including two confirmed partial responses and one unconfirmed partial response at a low dose of 8 mg QD, with additional unconfirmed responses at higher doses [5][6] - ERAS-0015 demonstrated approximately 8-21 times higher binding affinity to cyclophilin A compared to RMC-6236, and about 5 times greater potency in RAS inhibition, indicating its potential differentiation in the market [6] Safety and Pharmacokinetics - The safety profile of ERAS-0015 is favorable, with no dose-limiting toxicities reported and predominantly low-grade adverse events observed across all evaluated dose levels [5][6] - ERAS-0015 exhibits well-behaved, linear pharmacokinetics with no evidence of exposure plateau, suggesting a consistent pharmacological response [5][6] Company Overview - Erasca is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, co-founded by pioneers in precision oncology to create novel therapies aimed at shutting down the RAS/MAPK pathway [8]